UCB’s bimekizumab tops J&J’s Stelara in psoriasis study

UCB sets sights on rare diseases giant Alexion with Ra Pharm...

UCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage treatment for the rare muscle weakness disease myasthenia gravis to its R&D pipeline and sett

CHMP says no to Amgen’s osteoporosis drug Evenity

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns.

Success comes from listening to and working with patients

With the current mainstay of Parkinson’s treatment being more than 50 years old and doing nothing to slow or halt the progressive disease, the community is crying out for new drugs.

UCB joins with UK charity to research new epilepsy drugs

Belgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for people who have the disease, but do not respond to current treatments.